BRPI0517438A - composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica - Google Patents
composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêuticaInfo
- Publication number
- BRPI0517438A BRPI0517438A BRPI0517438-4A BRPI0517438A BRPI0517438A BR PI0517438 A BRPI0517438 A BR PI0517438A BR PI0517438 A BRPI0517438 A BR PI0517438A BR PI0517438 A BRPI0517438 A BR PI0517438A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- muscarinic
- treating
- pharmaceutical composition
- condition associated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 102000007216 Muscarinic M4 Receptor Human genes 0.000 title 1
- 108010008414 Muscarinic M4 Receptor Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compression, Expansion, Code Conversion, And Decoders (AREA)
- Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62178504P | 2004-10-25 | 2004-10-25 | |
| PCT/US2005/037271 WO2006047124A1 (en) | 2004-10-25 | 2005-10-18 | Thienopyridines as allosteric potentiators of the m4 muscarinic receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0517438A true BRPI0517438A (pt) | 2008-10-07 |
Family
ID=36021809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517438-4A BRPI0517438A (pt) | 2004-10-25 | 2005-10-18 | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8071776B2 (https=) |
| EP (1) | EP1807434B1 (https=) |
| JP (1) | JP4945453B2 (https=) |
| CN (1) | CN100577666C (https=) |
| AT (1) | ATE478876T1 (https=) |
| AU (1) | AU2005299957B2 (https=) |
| BR (1) | BRPI0517438A (https=) |
| CA (1) | CA2583550C (https=) |
| CY (1) | CY1111477T1 (https=) |
| DE (1) | DE602005023197D1 (https=) |
| DK (1) | DK1807434T3 (https=) |
| ES (1) | ES2349416T3 (https=) |
| MX (1) | MX2007004794A (https=) |
| PL (1) | PL1807434T3 (https=) |
| PT (1) | PT1807434E (https=) |
| WO (1) | WO2006047124A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9493481B2 (en) | 2012-02-23 | 2016-11-15 | Vanderbilt University | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2014035829A1 (en) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
| US9908893B2 (en) | 2013-06-11 | 2018-03-06 | Latvian Institute Of Organic Synthesis | Thieno [2,3-b] pyridines as multidrug resistance modulators |
| US9637498B2 (en) | 2013-08-23 | 2017-05-02 | Vanderbilt University | Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| US10329289B2 (en) | 2015-12-23 | 2019-06-25 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| MX385384B (es) | 2016-06-22 | 2025-03-18 | Univ Vanderbilt | Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4 |
| WO2018002760A1 (en) | 2016-07-01 | 2018-01-04 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| WO2018085803A1 (en) | 2016-11-07 | 2018-05-11 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| US10961253B2 (en) | 2016-11-07 | 2021-03-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2018085813A1 (en) * | 2016-11-07 | 2018-05-11 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| BR112019026955A2 (pt) | 2017-06-22 | 2020-06-30 | Pfizer Inc. | derivados de di-hidro-pirrolo-piridina |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| JP2021505581A (ja) | 2017-12-05 | 2021-02-18 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| WO2025201078A1 (zh) * | 2024-03-25 | 2025-10-02 | 四川科伦药物研究院有限公司 | 化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3430284A1 (de) * | 1984-08-17 | 1986-02-27 | Troponwerke GmbH & Co KG, 5000 Köln | Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung |
| MX9700696A (es) * | 1994-07-27 | 1997-04-30 | Sankyo Co | Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos. |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| GB9924962D0 (en) * | 1999-10-21 | 1999-12-22 | Mrc Collaborative Centre | Allosteric sites on muscarinic receptors |
| CN1249051C (zh) * | 2000-04-28 | 2006-04-05 | 阿卡蒂亚药品公司 | 毒蕈碱性激动剂 |
| CA2475773A1 (en) * | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| US6974870B2 (en) * | 2002-06-06 | 2005-12-13 | Boehringer Ingelheim Phamaceuticals, Inc. | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
-
2005
- 2005-10-18 BR BRPI0517438-4A patent/BRPI0517438A/pt not_active IP Right Cessation
- 2005-10-18 DK DK05812144.3T patent/DK1807434T3/da active
- 2005-10-18 WO PCT/US2005/037271 patent/WO2006047124A1/en not_active Ceased
- 2005-10-18 US US11/577,508 patent/US8071776B2/en not_active Expired - Fee Related
- 2005-10-18 CN CN200580036624A patent/CN100577666C/zh not_active Expired - Fee Related
- 2005-10-18 PL PL05812144T patent/PL1807434T3/pl unknown
- 2005-10-18 CA CA2583550A patent/CA2583550C/en not_active Expired - Fee Related
- 2005-10-18 EP EP05812144A patent/EP1807434B1/en not_active Expired - Lifetime
- 2005-10-18 DE DE602005023197T patent/DE602005023197D1/de not_active Expired - Lifetime
- 2005-10-18 JP JP2007537951A patent/JP4945453B2/ja not_active Expired - Fee Related
- 2005-10-18 MX MX2007004794A patent/MX2007004794A/es active IP Right Grant
- 2005-10-18 AU AU2005299957A patent/AU2005299957B2/en not_active Ceased
- 2005-10-18 PT PT05812144T patent/PT1807434E/pt unknown
- 2005-10-18 ES ES05812144T patent/ES2349416T3/es not_active Expired - Lifetime
- 2005-10-18 AT AT05812144T patent/ATE478876T1/de active
-
2010
- 2010-10-14 CY CY20101100921T patent/CY1111477T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8071776B2 (en) | 2011-12-06 |
| PL1807434T3 (pl) | 2011-02-28 |
| PT1807434E (pt) | 2010-09-22 |
| AU2005299957B2 (en) | 2011-04-21 |
| CN101048413A (zh) | 2007-10-03 |
| EP1807434B1 (en) | 2010-08-25 |
| CN100577666C (zh) | 2010-01-06 |
| ES2349416T3 (es) | 2011-01-03 |
| JP4945453B2 (ja) | 2012-06-06 |
| WO2006047124A1 (en) | 2006-05-04 |
| CY1111477T1 (el) | 2015-08-05 |
| EP1807434A1 (en) | 2007-07-18 |
| AU2005299957A1 (en) | 2006-05-04 |
| DK1807434T3 (da) | 2010-11-22 |
| JP2008517913A (ja) | 2008-05-29 |
| MX2007004794A (es) | 2007-07-09 |
| ATE478876T1 (de) | 2010-09-15 |
| CA2583550C (en) | 2013-05-14 |
| DE602005023197D1 (de) | 2010-10-07 |
| US20090105244A1 (en) | 2009-04-23 |
| CA2583550A1 (en) | 2006-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
| BRPI0715893A2 (pt) | composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono | |
| IL184932A0 (en) | Glucagon receptor antagonists, preperation and therapeutic uses | |
| WO2008077557A8 (en) | 8-ethinylxanthine derivatives as selective a2a receptor antagonists | |
| NO20091741L (no) | Pyrazolinforbindelser som mineralkortikoidreceptorantagonister | |
| ATE399770T1 (de) | Tachykininrezeptorantagonisten | |
| IL179599A0 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| TW200800943A (en) | Indane derivatives as MCH receptor antagonists | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| UA83868C2 (ru) | Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1 | |
| ECSP088939A (es) | Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
| BRPI0514579A (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto e gaboxadol, e, processo para preparo de um composto | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| CY1110453T1 (el) | Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| SI1853232T1 (sl) | Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo | |
| TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| DK1861360T3 (da) | Pyrrolidin-derivater som histamin-H3-receptorantagonister | |
| ATE523488T1 (de) | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung | |
| MX2009006346A (es) | Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos. | |
| MX2007005824A (es) | Agonistas y antagonistas del receptor de somatostatina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2328 DE 18-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |